Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.
Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.
Transcript
What role might genetic testing or the increasing number of approved companion diagnostics play to manage the escalating costs of oncology therapies?
So, genetic or biomarker testing is going to be critical moving forward, not only to manage costs—because we want to make sure that the patient is on the correct therapy, what their tumor mutations and their tumor looks like—it's also going to help for positive outcomes, which should also give us the correct duration of therapy, reduce side effects, and manage those types of adverse events that patients might have experienced otherwise that could defer them out of therapy because they were started on the wrong drug.
How are biosimilars currently fitting into strategies to manage costs in areas where biosimilars are approved?
Biosimilars are a great alternative to where we have brand name products or generic products to those. We're seeing biosimilar, or biobetter, strategies as a step through strategy. We're seeing biosimilars to be used first line, before we get to other drugs within the class. And the number of biosimilars that are getting approved yearly is great to see and have alternatives in care.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More